Update in Prevention and Treatment of HCV in People Who Inject Drugs

Registration


There isn't a cost to participate in this online course. The estimated time to complete this course is 45 minutes. Learners will be asked to complete an activity post-assessment with a passing score of 75%.

You must log in or create an account before enrolling in this educational activity. 

Once you register for the course, you will have 30 days from the date of enrollment to complete the course. The date your access expires will be indicated in the Course Summary box on this webpage.
 

Target Audience

Providers and clinical staff interested in providing treatment and care to individuals diagnosed with Hepatitis C virus (HCV) infection (providers, nurses, behavioral health, linkage navigators, front desk/scheduling, admin, etc.).

Learning Objectives

  • Discuss challenges that face patients, providers, and public health in reducing the burden of HCV for people who inject drugs (PWID).
  • Review potential solutions for preventing and treating HCV in PWID.

Speaker

Arthur Kim, MD

Dr. Kim is the Director of the Viral Hepatitis Clinic in the Division of Infectious Diseases at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. He received his medical degree at Harvard Medical School and trained in internal medicine at MGH and infectious diseases at MGH/Brigham and Women's Hospital. He expresses a longstanding interest in those living with HCV, especially in special populations such as acute infection, prisoners, post-transplantation, and HIV co-infection. He currently is co-PI or co-investigator of NIH-funded studies examining the immunology and immunogenetics of HCV infection. Dr. Kim serves on the AASLD/IDSA committee that provides online guidance at http://hcvguidelines.org. He focuses on HBV, HCV, and HIV/HCV co-infected patients. He especially welcomes referrals of those suspected of having an early or acute infection and/or drug use history. Dr. Kim also has many years of experience with inpatient transplant infectious disease and outpatient travel advice.

Medical Education

  • MD, Harvard Medical School
  • Residency, Massachusetts General Hospital
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Infectious Disease, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Full biography.

    Terms of Use and Privacy Policy

    Recording date: September 20, 2022
    Date of original release: September 23, 2022
    Most recent review/update: September 23, 2022
    Termination date: September 22, 2025

    Course summary
    Available credit: 
    • 0.75 AMA PRA Category 1 Credits™
    • 0.75 AOA Category 2­B
    • 0.75 CE Contact Hour(s)
    Course opens: 
    09/23/2022
    Course expires: 
    09/22/2025
    Cost:
    $0.00

    Accreditation Statements

    • MD:  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Primary Care Association. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.
    • DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 0.75 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
    • Other Healthcare Professionals: This live activity is designated for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.

    Educational Grants

    No ineligible company provided financial support for this continuing education activity. 

    DISCLOSURE

    The planning committee member(s) and speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The determination of educational content and the selection of speakers is the responsibility of the activity director. 

    Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.

    • Julie Baker, MPA, CHCEF - Planning Committee Member and Moderator
    • Kristi Barslou - Activity Coordinator
    • Mark Hillenbrand, MSW, LISW, RCSW - Planning Committee Member
    • Megan Srinivas, MD, MPH - Planning Committee Member
    • Megan Westerly, MSN, RN - Activity Coordinator and Moderator

    Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with ineligible companies to disclose. All relevant financial relationships have been mitigated.

    • Steven Donnelly, PharmD - Planning Committee Member, Speaker for Gilead
    • Douglas LaBrecque, MD - Planning Committee Member, Advisory Board Member for HepQuant
    • Arthur Kim, MD - Speaker, Kintor Pharmaceuticals, Data Monitoring Committee. The relationship is not relevant to the content of the educational activity. 

    Disclaimer

    The information provided at this activity is for continuing education. It is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.

    Available Credit

    • 0.75 AMA PRA Category 1 Credits™
    • 0.75 AOA Category 2­B
    • 0.75 CE Contact Hour(s)

    Price

    Cost:
    $0.00
    Please login or Create an Account to take this course.